1. Anticalculus Efficacy and Safety of a Stabilized Stannous Fluoride Dentifrice with Hexametaphosphate

Anticalculus Efficacy and Safety of a Stabilized Stannous Fluoride Dentifrice with Hexametaphosphate

Full text available in the Research Database at www.dentalcare.com

Reference: Schiff T, Saletta L, Baker RA, et al. Compend Contin Educ Dent. 2005; 26(9 suppl 1):29-34.

CONCLUSION

Over a 6-month period a stabilized stannous fluoride dentifrice with sodium hexametaphosphate showed superior anticalculus efficacy compared with a marketed tartar control triclosan/copolymer control.

OBJECTIVE

To assess the anticalculus efficacy of a 0.454% stabilized stannous fluoride dentifrice with sodium hexametaphosphate vs a positive control dentifrice.

MATERIALS AND METHODS

  • A 0.454% stabilized stannous fluoride dentifrice with sodium hexametaphosphate was compared to a marketed tartar control (0.30% triclosan/0.243% sodium fluoride/2% Gantrez copolymer) dentifrice.
  • The Volpe-Manhold Index was used to measure calculus on the lingual surfaces of the lower 6 anterior teeth.
  • Oral soft and hard tissue examinations were also conducted.
  • The Lobene Index was used to measure stain on the facial surfaces of 12 anterior teeth.
  • Subjects were randomized to either the stabilized stannous fluoride/sodium hexametaphosphate dentifrice or the control dentifrice..
  • Subjects used their assigned dentifrice twice a day for 6 months.
  • Subjects were examined again for calculus, stain, and soft tissue safety at months 3 and 6.

RESULTS

  • Data were analyzed for 80 subjects who had complete data.
  • Volpe-Manhold Index scores were statistically significantly lower for the stabilized stannous fluoride/sodium hexametaphosphate group than the triclosan/sodium fluoride copolymer group at both months 3 and 6 (P<0.0001).
  • Compared to the triclosan/sodium fluoride copolymer group, the stabilized stannous fluoride/sodium hexametaphosphate group showed a 54% reduction (adjusted means) in calculus accumulation at month 3 and a 56% reduction at month 6.
  • Neither group of subjects showed any appreciable extrinsic stain accumulation.
  • No adverse events were reported.
Adjusted Mean V-MI Score
  • Page 46 of 56